Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
May 09, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
May 07, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
March 06, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
February 22, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
January 22, 2024 07:00 ET
|
Apnimed, Inc.
Apnimed Announces New Leadership Appointments as It Builds Commercial & HR Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for OSA
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
December 21, 2023 08:30 ET
|
Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
Apnimed to Participate in Upcoming November Investor Conferences
November 06, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
October 31, 2023 20:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
October 18, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...